Veeva's Q1 2027 Highlights AI-First Adoption in Pharma and SaaS Shift

AI adoption in pharma: where it comes first and how investors should think about moving from SaaS to AI

1) Areas of pharma likely to adopt AI first (by “job type,” not by buzzword)

Management’s framework is that pharma isn’t primarily “transitioning apps into AI apps,” but moving toward a new technical architecture—MAAP: Models, Agents, and Applications—where existing Veeva applications become more efficient and users get AI help, and agents do substantial work so humans can focus on higher-value tasks. ¹

Within that, the excerpts point to three early adoption zones:

A. Clinical research operations: high-volume, document-heavy quality/sorting work

The clearest “first wave” described is around handling the huge volume of clinical research documents and related triage. Management cites ~100 million documents per year coming from clinical research sites that must be checked for quality and sorted correctly—work suited to agentic automation. ¹

They give concrete examples of what agents would do first:

• Sorting and categorizing inbound free text (e.g., identifying product complaint vs adverse event) and handling/triaging those records. ¹
• Extracting and classifying adverse event details such as what illness, severity, and trial involvement (e.g., “headache or throbbing headache,” “how serious,” and “what drug it’s involved with”). ¹

Why investors should care: this is operationally “high-volume repetitive labor” with a well-defined workflow where automation can be tested and improved incrementally. Management explicitly characterizes the best agentic labor as “high-volume repetitive work” that is currently outsourced. ²

B. Medical-legal-regulatory processes (commercial): automation of burdensome compliance workflows

On the commercial side, the excerpt distinguishes between:

• Agent “helper” use that augments field teams (drafting/delivering lightweight communications), and
• Automation of regulatory/medical-legal workflows that are described as “burdensome and expensive” and occupy significant time. ²

Management’s estimate: with the right agents, 70% or more of medical-legal-regulatory process work could be automated over time. ²

They also describe practical agent tasks (examples):

• An agent might help draft an email or send a text reminder on behalf of the representative. ²

Why investors should care: this suggests AI first targets back-office and documentation burden rather than replacing the relationship-driven “field person.” Management says the field person won’t be replaced; AI mainly augments productivity. ²

C. “Industry agentic labor” that integrates tightly with specialized life sciences systems

The adoption pattern is not “pharma builds agents themselves,” but “standardization via pre-built, industry-specific agents” that operate with Veeva’s applications. Management says Falcon is built to “designing and operating the standard agents for the industry rather than the industry having to hire humans for those specific jobs.” ³

They also emphasize a deployment reality: agents often need to become headless users of applications, and the platform must support that operating mode. ⁴

Why investors should care: this implies initial AI adoption depends on (1) integration maturity and (2) repeatability/standardization—less on one-off custom experimentation.

---

2) How investors should think about transitioning from traditional SaaS to AI in pharma

A. The transition is architectural: not just “AI inside apps,” but MAAP (Models + Agents + Applications)

Management explicitly rejects the framing that customers are simply transitioning from “applications into AI applications.” ¹

Instead, customers are “leaning into” a new technical architecture (MAAP), where:

• applications become more efficient with AI assistance, and
• customers work toward an “agentic biopharma” where agents do much of the work. ¹

Investors should therefore evaluate AI transition as a platform + workflow change, not a feature upgrade. Management states agents use models such as Anthropic or Gemini, but the key is the combination of models/agents with life-sciences applications. ¹

B. Expect two modes of AI value: in-app “Vault AI” and external “agent layer” (Falcon)

The excerpts describe two implementation layers:

1. Agents inside Vault applications that help users when humans are still actively operating. ⁴
2. Falcon (“agent layer”) where agents can operate as “users” of Veeva applications in a headless manner. ⁴

Management characterizes Falcon as “fully replacing parts” of jobs people previously did, delivering “agentic labor.” ⁴

Investor takeaway: the business impact is likely to come from a spectrum:

• augmentation (AI co-pilots inside existing workflows), and
• automation/deflection (agentic execution of standardized tasks).

C. Early adoption likely starts with standardized workflows; enterprise needs more adaptation than “Basics”

Management explains why uptake starts with smaller/nimble customers (“Veeva Basics”) and then expands:

• Basics run standard configurations and processes, so agents can work smoothly because configuration and usage patterns are consistent. ⁵
• For larger enterprises, agents must be more adaptive: first the system learns “how that customer is using that Vault,” tests compatibility, then iterates if there are classification differences. ⁵

This implies investors should not assume uniform rollout speed across customer segments; adoption friction may be lower where process standardization is higher. ⁵

D. The economics lens: AI shifts cost structure and changes the outsourcing/insourcing boundary

Even though the question is “how should investors think,” the excerpts provide a cost/economic logic for adoption:

• Agentic labor targets high-volume repetitive work that is outsourced, enabling pharma to do some of it cheaper, faster, better. ²
• That could be “beneficial for the CROs” because agents handle lower volume work while CROs may retain the “higher margin work” (as characterized in the excerpt). ²

Investor takeaway: AI adoption in pharma is partly an outsourcing displacement story (where the “traditional spend bucket” may shift), and partly a work enablement story (where pharma can run more trials and thereby expand spend in other places). Management explicitly links agentic automation to letting pharma “run more trials” and states higher margin CRO work may remain. ²

E. Investable takeaway: adoption will require change management and integration, not only model performance

Management stresses that beyond technology, “a lot of this is about change management.” ⁶
They also describe the agents’ success dependence on customers’ systems and data flows, because agents must use applications headlessly and operate reliably. ⁴

F. Evidence of momentum in the commercial/CRM layer: customers are already “turning on AI”

While the question is about “pharma transition,” management provides an observable proxy for commercialization readiness: in Vault CRM, management says there are customers “turning on AI at Vault CRM,” alongside pipeline and engagement improvements. ⁷

They also say Veeva has over 150 customers live on Vault CRM and over 40 migrations, and that execution and innovation are showing up in customer behavior (AI usage). ⁷

Investor takeaway: it suggests the transition is progressing from concept to operational deployment, at least within CRM, which can be a leading indicator of how quickly life-sciences customers adopt standardized AI capabilities. ⁷

---

3) Putting it together: a practical investor framework

Based on the excerpts, investors should frame the AI transition as:

1. Targeted first adoption in “agentic labor” workloads: document triage, quality checks, classification, and other high-volume repetitive tasks. ¹²
2. Commercial AI first in compliance/medical-legal automation (with a stated potential of 70%+ over time) and augmentation of field productivity rather than replacement. ²
3. Business-model/platform impact via MAAP: value comes from integrating models + agents + life-sciences applications, including headless execution for standardized work. ¹⁴
4. Segment-dependent rollout: “Basics” should adopt faster due to standard configurations; enterprises require more adaptation/testing. ⁵
5. Economic reallocation: automation likely shifts some outsourced repetitive work toward pharma/enablement, while higher-margin external work (as characterized) can remain elsewhere. ²

This is a fundamentally different lens than “traditional SaaS with a new AI feature,” because management’s stated goal is agentic execution of standardized slices of jobs supported by deep industry application integration. ⁴³